Please assess the completion status of the following clinical trial:

Trial Title: Kaletra-isentress Treatment Evaluation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1-infected individuals receiving HAART regimen (if on PI-based regimen, must be 1st PI-containing HAART).~* They must have been on and tolerating current HAART regimen for \> 6-months.~* Plasma HIV-1 viral load \< 50 copies/ml at study entry.~* Men and women age \> 18 years (sex is defined as sex at birth).~* Laboratory values obtained within 30 days prior to study entry:~  * Hemoglobin \> 9.4 g/dl~ * Creatinine \< 2 mg/dl~ * AST (SGOT) \< 2 x ULN~ * ALT (SGPT) \< 2 x ULN~* Ability and willingness of subject or legal guardian/representative to give written informed consent.~* No CD4 T-cell counts requirement~Exclusion Criteria:~* Subjects with a history of previous intolerance to or virological failure to LPV/r~* Concomitant drugs (including alternative therapies) that may affect PI or RAL plasma concentrations (inducers or inhibitors of the CYP 3A4 or UDP-glucuronosyltransferase iso-enzymes).~* A known history of noncompliance with medications or a known history of noncompliance with scheduled physician and clinic visits.~* Investigational ARV drug.~* Pregnancy/Breast feeding.~* HBV-coinfected patients receiving nucleoside analogue for both HIV and HBV suppression.~* Active drug or alcohol use or dependence which, in the Investigator's opinion, may interfere with adherence to study requirements or endanger subject's health while on the study.~* Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Kaletra + Isentress (Type: EXPERIMENTAL): Kaletra + Isentress
- Standard HAART (Type: ACTIVE_COMPARATOR): Pre-study Antiretroviral regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).